Some people with Medicare can access certain GLP-1 medications for weight management starting this year by paying a $50 copayment for a monthly supply, but this benefit is not available to all beneficiaries or for every medication in this category.
The program is called Medicare GLP-1 Bridge and started on July 1, 2026. The Centers for Medicare and Medicaid Services (CMS) maintain it as a temporary program for individuals who have Part D drug coverage and meet certain medical criteria.
According to the official information from Medicare, Foundayo, Wegovy, and certain presentations of Zepbound are currently included.
The program is scheduled until December 31, 2027.
What GLP-1 medications are included?
Medicare currently identifies three medications that can be obtained through the GLP-1 Bridge when used to reduce excess weight or maintain weight loss:
Foundayo: in tablet form.
Wegovy: in injection or tablet form.
Zepbound: exclusively the KwikPen presentation.
In the case of Zepbound, Medicare specifies that the program does not cover vials or single-dose pens.
The list may change, so it's advisable to check the official Medicare page on weight loss drugs again before starting the process.
The price is $50 for a monthly supply
Beneficiaries who qualify pay a copayment of 50 dollars for a 28 or 30-day supply, depending on the medication.
The amount does not change based on the beneficiary's income level.
However, there is an important difference with the medications that are typically obtained through Part D: the GLP-1 Bridge operates outside the usual payment system of that coverage.
This means that those 50 dollars:
They do not count towards the annual deductible of the medication plan.
They do not count towards the annual out-of-pocket spending limit for Part D.
They cannot be reduced through the Medicare Additional Assistance program.
They cannot be distributed over several months through the Medicare Prescription Payment Plan.
CMS also establishes that coupons and certain discount programs cannot be used to lower the copayment for the GLP-1 Bridge.
It’s not enough to have Medicare
To access the program, the individual must have Medicare Part D medication coverage.
This can be through a standalone drug plan or certain Medicare Advantage plans that include drug coverage, among other accepted options.
However, certain clinical criteria must also be met.
Who can qualify based on their BMI?
Medicare establishes three main eligibility pathways for adults aged 18 and older.
First: having a body mass index (BMI) of 35 or higher.
In that case, it is not necessary to have one of the additional diseases required in the other groups to meet the program's BMI criteria.
Second: to have a BMI of 30 or higher along with at least one of these conditions:
Heart failure with preserved ejection fraction.
Difficult-to-control hypertension.
Chronic kidney disease stage 3a or higher.
Third: to have a BMI of 27 or higher and also at least one of the following conditions:
Prediabetes.
Having previously suffered a myocardial infarction.
Having suffered a stroke.
Symptomatic peripheral arterial disease.
The BMI should be assessed when starting treatment with GLP-1.
Who cannot use the GLP-1 Bridge
The program is primarily designed to broaden access to these medications when used for weight management.
A person cannot use the GLP-1 Bridge if they are already receiving a GLP-1 covered by their own Medicare drug plan.
Medicare also states that those with type 2 diabetes, moderate to severe obstructive sleep apnea, or certain liver diseases may be eligible to receive a GLP-1 directly through their standard Part D coverage to treat those conditions.
In those cases, you should check the coverage with your plan instead of resorting to the GLP-1 Bridge.
CMS explains that the goal is to prevent medications that may already be covered under Part D for a medical indication from being artificially moved to the special $50 program.
How to request the medication
The process does not begin by filling out a standalone application with Medicare.
If a person believes they meet the requirements, they should first speak with their doctor or another healthcare professional to determine if one of these medications is appropriate for their situation.
When appropriate, the professional sends the prescription to the pharmacy.
You will also need to complete a pre-authorization when required to demonstrate that the patient meets the program criteria.
Medicare also indicates that the professional must certify that the patient is using the medication as part of a lifestyle program that includes attention to diet and exercise.
The authorization may last until the end of 2027
When the prior authorization is approved, the beneficiary receives a communication from Medicare informing them that the medication is covered by the GLP-1 Bridge.
According to Medicare, that authorization can remain valid, including refills and dose changes, until December 31, 2027, unless the patient switches to another GLP-1 medication.
In that case, a new authorization may be necessary.
What happens if you are already taking a GLP-1?
Currently taking one of these medications does not necessarily prevent access to the program, but it depends on how it is being paid for.
If the GLP-1 is already being covered by the beneficiary's Medicare drug plan, the GLP-1 Bridge cannot be used simply to replace that coverage with the $50 copayment.
The person should continue obtaining the medication through their Part D plan.
If you are paying for the medication through another means and believe you meet the criteria for the GLP-1 Bridge, Medicare recommends consulting your doctor to verify eligibility.
The program operates throughout the United States
The Medicare GLP-1 Bridge is available in all states and territories of the United States for eligible individuals.
Beneficiaries can use the tool available at Medicare.gov to preliminarily check if they may meet the requirements.
You can also contact 1-800-MEDICARE (1-800-633-4227) for inquiries regarding eligibility or the status of a prior authorization.
Do not confuse it with the regular medication coverage
The GLP-1 Bridge is especially relevant now as beneficiaries begin to review their options for the upcoming year.
CiberCuba reported recently that Medicare now allows the comparison of available plans for 2027, ahead of the annual Open Enrollment period starting on October 15.
When comparing plans, it remains important to check which medications are directly covered by each Part D option, along with their prior authorization requirements, deductibles, and copayments.
The GLP-1 Bridge does not replace that review: it is a separate and temporary program specifically designed for certain beneficiaries who need these treatments for weight management and meet the criteria set by CMS.
Four questions to determine if it's worth consulting a doctor
Do you currently have Medicare Part D drug coverage?
Isn't your GLP-1 medication already covered by that Part D?
Does it meet any of the BMI criteria and medical conditions established by Medicare?
Would the medication be used for weight loss or to maintain weight loss?
If the responses indicate potential eligibility, the next step is to consult with a healthcare professional and use the official Medicare tool. The $50 copay does exist, but it does not constitute automatic coverage for anyone with Medicare or for any GLP-1 prescription.
Related videos:
Filed under: